Cidofovir Shortage Affects HIV Positive Patients with Cytomegalovirus Retinitis

Cidofovir Shortage Affects HIV Positive Patients with Cytomegalovirus Retinitis

Cidofovir CAS 113852-37-2As an antiviral medication used to treat cytomegalovirus retinitis, also known as CMV in patients infected with the HIV virus, the current Cidofovir shortage is alarming (see the FDA Cidofovir shortage posting). Administered as an injectable treatment intravenously, the dosing of Cidofovir can take up to six hours to complete. The treatment of 75 mg/ml is dispensed once a week for two weeks in a row, and then once every two weeks until the infection has been eradicated.  Cidofovir is regularly given alongside the oral medication Probenecid, and there are no comparable substitute treatment options for patients who are HIV positive and suffering from CMV. While this antiviral medication is considered to be a complicated protocol for administration, the potency of Cidofovir is second to none. Recent research regarding the use of Cidofovir for off-label treatment has brought to light additional information in support of this formidable drug.

In the spring of 2013, at the HHV6 Conference in France, the benefits of Cidofovir were touted specifically for the treatment of patients with Herpes virus infected Chronic Fatigue Syndrome. Results from a lengthy study involving 65 patients who had both chronic fatigue syndrome and Human Herpes virus 6 {HHV6} or human cytomegalovirus {HCMV} were supportive of the use of Cidofovir. The patients were given regular infusion treatments with Cidofovir between the years of 2005 and 2012, along with frequent blood tests to be sure there was no kidney damage in the patients studied. As a unique retrospective antiviral study, the evaluation of Cidofovir for these patients proved to have positive results. Roughly 70 percent of patients were able to resume a normal “healthy” lifestyle after their treatment with Cidofovir, alongside Probenecid, was completed. This hefty percentage of patients reported that they felt well enough to return to their full or part time work and life duties after being successfully treated with Cidofovir and Probenecid. There were minimal side effects, and these were due to the adjunctive treatment of Probenecid, not from the use of Cidofovir. Additionally, many physicians use Cidofovir for the off-label treatment of diseases such as human papillomavirus, vaccinia virus infections and the herpes simplex virus.

If you are a researcher, developer or are experiencing a Cidofovir shortage, LGM Pharma can provide you the Cidofovir CAS# 113852-37-2 API for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service